# Ameluz (ameluz) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ameluz

> The FDA approved Ameluz (ameluz), sponsored by Biofrontera Inc. (BFRI), on September 14, 2026 for superficial Basal Cell Carcinoma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ameluz (ameluz) |
| Codes |  |
| Sponsor | Biofrontera Inc. (BFRI) https://sec-api.dev/companies/bfri/catalysts |
| Indications | superficial basal cell carcinoma, superficial basal |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2024: label expansion decision

- Status: completed, approved. Date confidence: month.
- First seen 2024-11-14, last confirmed 2025-12-05.
- SEC registration statement (S-1) (accession 0001493152-25-026443): "October 2024, the FDA approved the Company's Supplemental New Drug Application to increase the maximally approved dosage of Ameluz® from one to three tubes per treatment." https://www.sec.gov/Archives/edgar/data/1858685/000149315225026443/forms-1.htm
- SEC registration statement (S-1) (accession 0001641172-25-019928): "October 2024, the FDA approved the Company's Supplemental New Drug Application to increase the maximally approved dosage of Ameluz® from one to three tubes per treatment." https://www.sec.gov/Archives/edgar/data/1858685/000164117225019928/forms-1.htm
- SEC Form 10-K (accession 0001493152-25-011052): "October 2024, the FDA approved the Company's Supplemental New Drug Application to increase the maximally approved dosage of Ameluz® from one to three tubes per treatment." https://www.sec.gov/Archives/edgar/data/1858685/000149315225011052/form10-k.htm
- SEC registration statement (S-1) (accession 0001493152-25-002844): "In October 2024, the FDA approved the Company's Supplemental New Drug Application to increase the maximally approved dosage of Ameluz® from one to three tubes per treatment." https://www.sec.gov/Archives/edgar/data/1858685/000149315225002844/forms-1.htm
- SEC registration statement (S-1) (accession 0001493152-25-002844): "October 2024, the FDA approved the Company's Supplemental New Drug Application to increase the maximally approved dosage of Ameluz® from one to three tubes per treatment." https://www.sec.gov/Archives/edgar/data/1858685/000149315225002844/forms-1.htm
- SEC Form 10-Q (accession 0001493152-24-045220): "In October 2024, the FDA approved the Company's Supplemental New Drug Application to increase the maximally approved dosage of Ameluz® from one to three tubes per treatment." https://www.sec.gov/Archives/edgar/data/1858685/000149315224045220/form10-q.htm
- SEC Form 10-Q (accession 0001493152-24-045220): "October 2024, the FDA approved the Company's Supplemental New Drug Application to increase the maximally approved dosage of Ameluz® from one to three tubes per treatment." https://www.sec.gov/Archives/edgar/data/1858685/000149315224045220/form10-q.htm

### February 9, 2026: topline data readout

- Status: completed, met. Date confidence: exact. Stage: 3.
- First seen 2026-02-09, last confirmed 2026-02-09.
- Press release filed with the SEC (EX-99) (accession 0001493152-26-005717): "(February 9, 2026) — Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced positive and statistically significant top-line results from its Phase 3 clinical trial evaluating Ameluz® PDT with the red-light LED (RhodoLED®)" https://www.sec.gov/Archives/edgar/data/1858685/000149315226005717/ex99-1.htm

### September 14, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: Superficial Basal Cell Carcinoma.
- First seen 2026-09-14, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001493152-26-042508): "Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma" https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-051546): "September 9, 2026 FDA Approval of Ameluz on September for the treatment of Superficial Basal" https://www.sec.gov/Archives/edgar/data/1858685/000149315226051546/ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ameluz.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ameluz (ameluz) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ameluz

```bibtex
@misc{secapidev_pdufa_ameluz_20261116,
  title        = {Ameluz (ameluz) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ameluz}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ameluz_20261116","title":"Ameluz (ameluz) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ameluz","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
